Welcome to our dedicated page for Precision Biosciences SEC filings (Ticker: DTIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Precision BioSciences, Inc. (Nasdaq: DTIL) provides access to the company’s official regulatory disclosures as a clinical stage gene editing company. These documents offer detailed information on its ARCUS-based in vivo gene editing programs, financial condition, capital raising activities, and other material events relevant to shareholders and analysts.
Among the key filings are Current Reports on Form 8-K, which Precision uses to report significant developments. Examples include an 8-K describing an underwritten offering of common stock, pre-funded warrants, and warrants, with net proceeds intended to fund ongoing and planned research and development, working capital, and general corporate purposes. Other 8-Ks furnish press releases on clinical data from the ELIMINATE-B trial of PBGENE-HBV, updates on PBGENE-DMD, quarterly financial results, and executive employment arrangements.
Filings related to PBGENE-HBV summarize clinical findings such as dose-dependent antiviral activity, reductions in hepatitis B surface antigen (HBsAg), biopsy evidence of ARCUS-mediated viral DNA editing, and safety data across multiple cohorts. These reports help readers understand how Precision evaluates safety, efficacy, and dosing strategy for its hepatitis B program. Additional disclosures describe regulatory designations, trial expansion plans, and the structure of ongoing Phase 1/2a studies.
For capital markets activity, SEC filings detail the terms of equity offerings, including the number of shares and warrants issued, exercise prices, and intended use of proceeds. Exhibits to these filings may include underwriting agreements, warrant forms, and legal opinions on the validity of securities.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping users quickly grasp the implications of new 8-Ks and other reports. Real-time updates from EDGAR, combined with structured access to items such as clinical trial updates, financing transactions, and governance changes, make this page a focused resource for reviewing Precision BioSciences’ regulatory history and ongoing obligations.
DTIL reported Form 144 transactions involving restricted stock vesting and a recent resale. The filing shows 4,925 common shares listed under "Securities To Be Sold" with an event date of
DTIL reported an insider sale notice for common stock under Form 144. The filing lists 4,925 shares as restricted stock vesting to be sold on
DTIL reported a Form 144 filing in which Michael Amoroso indicated a sale of 34,799 common shares on
DTIL insider John A. Kelly filed a Form 144 reporting a proposed sale of 8,149 common shares that vested as restricted stock on
Tang Capital Management and related entities report that they no longer own any Precision BioSciences, Inc. common stock. In Amendment No. 3 to their Schedule 13G, they state beneficial ownership of 0 shares, representing 0% of the company’s common stock as of December 31, 2025.
Each reporting person lists zero sole or shared voting power and zero sole or shared dispositive power over Precision BioSciences shares. They also certify that any securities previously held were not acquired or held to change or influence control of the company.
Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of 993,913 shares of Precision BioSciences, Inc. common stock, equal to 4.1% of the class as of the calculation date. They hold shared voting and dispositive power over all reported shares, with no sole authority.
The ownership percentage is based on 24,071,751 shares of common stock outstanding, combining 10,815,000 shares issued in a recent offering with 13,256,751 shares outstanding as of October 29, 2025. The reporting persons certify the position is not held to change or influence control of the company.
Bleichroeder LP and related entities have reported a significant ownership position in Precision Biosciences, Inc. They are deemed to beneficially own 1,900,000 common shares, representing 8.21% of the company’s common stock believed to be outstanding as of 12/31/2025.
The shares are held for various advisory clients of Bleichroeder LP, which is a registered investment adviser. Clients have the right to receive dividends and sale proceeds from these securities. The filing states that the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Precision Biosciences.
Precision BioSciences received U.S. FDA clearance of an investigational new drug application for PBGENE-DMD, its first-in-class in vivo gene editing therapy for Duchenne muscular dystrophy. This “Study May Proceed” notification allows initiation of site activation for the Phase 1/2 FUNCTION-DMD clinical trial in ambulatory patients.
PBGENE-DMD uses a gene excision approach to permanently correct dystrophin gene mutations between exons 45 and 55, a region affecting about 60% of boys with Duchenne muscular dystrophy. The therapy is designed to restore near full-length dystrophin protein at about 80% of normal size, substantially larger than micro-dystrophin constructs approved or in development.
The company plans to activate the first U.S. clinical site in the first half of 2026 and expects initial data from multiple patients by year end 2026. PBGENE-DMD has Rare Pediatric Disease and Orphan Drug designations, and a virtual investor event is planned in March to discuss the program and trial.
Precision BioSciences, Inc. received a significant ownership disclosure from Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia. The reporting group beneficially owns 2,328,485 common shares of Precision BioSciences, equal to 9.99% of the class.
The stake consists of 1,917,995 common shares held directly and 410,490 common shares issuable upon exercise of warrants. These percentages are based on 22,897,665 common shares outstanding as of December 30, 2025, as referenced from a Form S-3. The warrants are subject to a 9.99% beneficial ownership blocker, so they cannot be exercised if doing so would push the group above that threshold.
Voting and dispositive power over all 2,328,485 shares are reported as shared among the reporting persons. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Precision BioSciences.
Aberdeen Group plc and abrdn Inc. have disclosed a significant ownership stake in Precision BioSciences Inc. (DTIL). The reporting entities beneficially own 2,138,603 shares of Precision BioSciences common stock, representing 8.88% of the outstanding shares of this class as of 12/31/2025. They report zero sole voting or dispositive power, and shared voting and shared dispositive power over all 2,138,603 shares.
The firms state that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Precision BioSciences, nor in connection with any transaction intended to have that effect. abrdn Inc. indicates that it beneficially owns these shares on behalf of underlying clients, with Aberdeen Group plc as the parent company and abrdn Holdings Limited as intermediate holding company.